A Randomized, Double-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Administration of XTL6001 Injection in Healthy and Obese Subjects
Latest Information Update: 09 Oct 2025
At a glance
- Drugs XTL 6001 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Shanghai Xitaili Biomedicine Technology
Most Recent Events
- 09 Oct 2025 New trial record